awmsg logo



lenvatinib (Lenvima®)


Reference No. 976

Publication date:
19/10/2017


Appraisal information

lenvatinib (Lenvima®) 4 mg capsule
lenvatinib (Lenvima®) 10 mg capsule


Company: Eisai Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 06/09/2017
AWMSG meeting date: 11/10/2017
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 1817
Ratification by Welsh Government: 18/10/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA535). NICE GUIDANCE ISSUED JULY 2018 (Refer to NICE website for full guidance on NICE recommmendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download